公开(公告)号：US20230270719A1

公开(公告)日：2023-08-31

申请号：US18059806

申请日：2022-11-29

申请人： Gilead Sciences, Inc.

发明人： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC分类号： A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

CPC分类号： A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

摘要： This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US20230141913A2

公开(公告)日：2023-05-11

申请号：US17270652

申请日：2019-08-23

申请人： XENIOPRO GmbH

发明人： Viktoria REINMÜLLER ,  Roman MARTY ,  Olivier WAGNIÉRES ,  Jean-Baptiste GUALTIEROTTI ,  Verena KÜPPERS

IPC分类号： A61K31/5375 ,  C07C43/275 ,  C07D213/647 ,  A61K31/09 ,  A61K31/44 ,  A61P35/02 ,  A61P35/00 ,  C07D295/096 ,  C07D453/02 ,  A61K31/351 ,  A61K31/451 ,  A61K31/495 ,  A61K31/439 ,  C07D305/06 ,  C07D331/04 ,  C07D205/04 ,  A61K31/337 ,  A61K31/38 ,  A61K31/397 ,  C07D407/12 ,  C07D411/12 ,  C07D405/12 ,  C07D409/12 ,  C07D401/12 ,  A61K31/5377 ,  A61K31/496 ,  C07D309/04 ,  A61K31/12 ,  A61K31/085 ,  C07C49/255 ,  C07C43/295 ,  C07C205/04 ,  C07C251/20 ,  C07C251/48 ,  A61K31/04 ,  A61K31/15 ,  A61K39/39

CPC分类号： A61K31/5375 ,  C07C43/275 ,  C07D213/647 ,  A61K31/09 ,  A61K31/44 ,  A61P35/02 ,  A61P35/00 ,  C07D295/096 ,  C07D453/02 ,  A61K31/351 ,  A61K31/451 ,  A61K31/495 ,  A61K31/439 ,  C07D305/06 ,  C07D331/04 ,  C07D205/04 ,  A61K31/337 ,  A61K31/38 ,  A61K31/397 ,  C07D407/12 ,  C07D411/12 ,  C07D405/12 ,  C07D409/12 ,  C07D401/12 ,  A61K31/5377 ,  A61K31/496 ,  C07D309/04 ,  A61K31/12 ,  A61K31/085 ,  C07C49/255 ,  C07C43/295 ,  C07C205/04 ,  C07C251/20 ,  C07C251/48 ,  A61K31/04 ,  A61K31/15 ,  A61K39/39

摘要： The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

公开(公告)号：US20230113351A1

公开(公告)日：2023-04-13

申请号：US18053648

申请日：2022-11-08

申请人： Diamond Therapeutics Inc.

发明人： Judith BLUMSTOCK ,  William J. TYLER

IPC分类号： A61K31/675 ,  A61P25/28 ,  A61K31/05 ,  A61K31/12 ,  A61K31/137 ,  A61K31/38 ,  A61K31/4045 ,  A61K31/4164 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/48 ,  A61K31/496 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/554 ,  A61K31/573 ,  A61K31/685 ,  A61K33/06 ,  A61K36/258

摘要： Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. Also disclosed herein are pharmaceutical compositions, formulations. and dosage forms of 5HT receptor agonists.

公开(公告)号：US20220265595A1

公开(公告)日：2022-08-25

申请号：US17606884

申请日：2020-04-30

申请人： Sitryx Therapeutics Limited

发明人： Michael Liam COOKE ,  David COUSIN ,  Matthew Colin Thor FYFE ,  Barry John TEOBALD ,  Stephen Malcolm THOM ,  Thomas Michael WAUGH

IPC分类号： A61K31/225 ,  C07C255/14 ,  C07C317/18 ,  C07C69/593 ,  C07D305/08 ,  C07D207/27 ,  C07C233/05 ,  C07D207/273 ,  C07C311/03 ,  C07C219/08 ,  C07D307/20 ,  C07D309/12 ,  C07D211/96 ,  C07D295/08 ,  C07D331/04 ,  C07D205/04 ,  C07D295/088 ,  C07D207/277 ,  C07D257/04 ,  C07D519/00 ,  C07D451/10 ,  A61K31/275 ,  A61K31/337 ,  A61K31/4015 ,  A61K31/341 ,  A61K31/351 ,  A61K31/445 ,  A61K31/5375 ,  A61K31/38 ,  A61K31/397 ,  A61K31/495 ,  A61K31/54 ,  A61K31/41 ,  A61K31/46

摘要： The invention relates to compounds of formula (IW-1) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA, RB, RC and RD are as defined herein.

公开(公告)号：US20220249500A1

公开(公告)日：2022-08-11

申请号：US17270652

申请日：2019-08-23

申请人： XENIOPRO GmbH

发明人： Viktoria REINMÜLLER ,  Roman MARTY ,  Olivier WAGNIÈRES ,  Jean-Baptiste GUALTIEROTTI ,  Verena KÜPPERS

IPC分类号： A61K31/5375 ,  C07C43/275 ,  C07D213/647 ,  A61K31/09 ,  A61K31/44 ,  A61P35/02 ,  A61P35/00 ,  C07D295/096 ,  C07D453/02 ,  A61K31/351 ,  A61K31/451 ,  A61K31/495 ,  A61K31/439 ,  C07D305/06 ,  C07D331/04 ,  C07D205/04 ,  A61K31/337 ,  A61K31/38 ,  A61K31/397 ,  C07D407/12 ,  C07D411/12 ,  C07D405/12 ,  C07D409/12 ,  C07D401/12 ,  A61K31/5377 ,  A61K31/496 ,  C07D309/04 ,  A61K31/12 ,  A61K31/085 ,  C07C49/255 ,  C07C43/295 ,  C07C205/04 ,  C07C251/20 ,  C07C251/48 ,  A61K31/04 ,  A61K31/15 ,  A61K39/39

摘要： The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

公开(公告)号：US11179414B2

公开(公告)日：2021-11-23

申请号：US16375986

申请日：2019-04-05

申请人： LAIMU CORPORATION

发明人： Sachio Wakayama

IPC分类号： A61K31/728 ,  C08B37/08 ,  C07D307/62 ,  A61K31/341 ,  C12N9/50 ,  A61P17/02 ,  A61K38/00 ,  A61K9/00 ,  A61K31/38 ,  A61P17/16

摘要： Disclosed is a method for producing a protease degradation composition by degrading a composition containing a hyaluronic acid and a protein with a protease, in the presence of an ascorbic acid, an ascorbate or a salt thereof. The composition produced according to the method has a high fibroblast proliferation promoting effect and a high collagen production promoting effect.

公开(公告)号：US20210251957A1

公开(公告)日：2021-08-19

申请号：US17089030

申请日：2020-11-04

申请人： GILEAD SCIENCES, INC.

发明人： Jinfa DU ,  Joshua A. KAPLAN ,  Thorsten A. KIRSCHBERG ,  Tetsuya KOBAYASHI ,  Scott E. LAZERWITH ,  Rick Andrew LEE ,  Jonathan William MEDLEY ,  Michael L. MITCHELL ,  Philip Anthony MORGANELLI ,  Hyung-Jung PYUN ,  Sophia L. SHEVICK ,  Neil H. SQUIRES ,  William J. WATKINS

IPC分类号： A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

摘要： This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US10851075B2

公开(公告)日：2020-12-01

申请号：US16161413

申请日：2018-10-16

申请人： Sumitomo Dainippon Pharma Oncology, Inc.

发明人： Zhiwei Jiang ,  Chiang Jia Li ,  Wei Li ,  David Leggett

IPC分类号： C07D333/74 ,  A61K31/343 ,  C07D307/92 ,  A61K31/38 ,  A61P35/00

摘要： The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.

公开(公告)号：US20200316173A1

公开(公告)日：2020-10-08

申请号：US16712816

申请日：2019-12-12

申请人： Rappaport Family Institute for Research in the Medical Sciences

发明人： Yuval Shaked

IPC分类号： A61K38/17 ,  G16H20/10 ,  G16B15/20 ,  A61K31/38 ,  C07K16/28 ,  C07K16/22 ,  A61P35/00

摘要： A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.

公开(公告)号：US10761087B2

公开(公告)日：2020-09-01

申请号：US16063047

申请日：2016-12-16

申请人： Link Genomics, Inc. ,  ROHTO Pharmaceutical Co., Ltd.

发明人： Shinichiro Niwa ,  Dai Ogura ,  Hidemi Mizunuma ,  Yoko Arai ,  Takahiro Kurose ,  Yoshihiro Takai ,  Yoko Mitsuguchi ,  Mariyo Moriya

IPC分类号： G01N33/50 ,  A61K31/436 ,  A61K31/192 ,  A61K31/38 ,  A61K31/404 ,  A61K31/421 ,  A61K31/426 ,  A61K31/47 ,  A61K31/41 ,  A61K45/00 ,  A61P27/02 ,  A61K45/06

摘要： The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.